Comparison of intrabody-mediated degradation of mHTT through ubiquitin independent vs. dependent pathways
DOI:
https://doi.org/10.61173/et5ndt09Keywords:
mutant Huntingtin, intrabody, degron, prote-olysis, aggregationAbstract
Huntington’s disease (HD) is a progressive brain disorder that causes various symptoms, such as uncontrolled movements, emotional problems, and cognitive deficits. In US there are more than 40,000 patients with HD disease and the global prevalence is between 1/10,000 to 1/20,000 based on the information from Huntington’s Disease Society of America. HD is caused by a mutation in Huntingtin gene (HTT) coding for the mutant Huntington (mHtt) protein. The mHtt protein causes neural cell death, leading to symptoms in HD patients. Degrons are degradation signals located in some proteins that direct misfolded or aggregated proteins to Ubiquitin–Proteasome System (UPS) for degradation. Intrabody is a small recombinant antibody that targets antigens intracellularly. Anti-mHtt intrabodies were found to be able to promote mHtt degradation and degrons can enhance the intrabody-mediated mHtt degradation. By involving various degrons, intrabodies can work through either ubiquitin-dependent or ubiquitin-independent pathway to degrade mutant proteins. However, the mechanism underlying the mHtt degradation mediated by intrabody is not fully understood and the efficiency of each degradation pathway involved is unclear. To investigate which of the above pathways is more efficient, we compared the intrabody-mediated degradation pathways with CL1 vs. PEST degrons fused to the intrabody. Results showed that the ubiquitin-dependent proteasome pathway involving CL1 degron is more efficient in mHtt degradation than the ubiquitin-independent proteasome pathway involving PEST degron. These results provide the scientific foundation of developing a potential intrabody-mediated treatment for HD disease via the ubiquitin-dependent pathway.
References
[1] Rubinsztein. (2003). The molecular pathology of Huntington’s Disease (HD). Curr. Med. Chem.-Immun., Endoc, & Metab. Agents, 3 (4), 329-340.
[2] Finkbeiner. (2011). Huntington’s Disease. Cold Spring Harb Perspect Biol; 3:a007476
[3] Chiara Zuccato, Marta Valenza, Elena Cattaneo. (2010). Molecular mechanisms and potential therapeutical targets in Huntington’s disease. Physiol Rev. 90(3): 905-81.
[4] Hakim-Eshed et al., (2020). Site-specific ubiquitination of pathogenic huntingtin attenuates its deleterious effects. PNAS. 117 (31), 18661-18669.
[5] Hipp et al. (2012). Indirect inhibition of 26S proteasome activity in a cellular model of Huntington’s disease. J. Cell Biol. 196 (5) 573–587.
[6] Kvam E, Nannenga BL, Wang MS, Jia Z, Sierks MR, et al. (2009). Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. PLoS One. 4: e5727.
[7] Lecerf J-M, Shirley TL, Zhu Q, Kazantsev A, Amersdorfer P, et al. (2001). Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington’s disease. PNAS. 98: 4764–4769.
[8] Miller TW, Zhou C, Gines S, MacDonald ME, Mazarakis ND, et al. (2005). A human single-chain Fv intrabody preferentially targets amino-terminal huntingtin fragments in striatal models of Huntington’s disease. Neurobiol Dis. 19: 47–56.
[9] Murphy RC, Messer A. (2004). A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington’s disease. Brain Res Mol Brain Res 121: 141–145.
[10] McLear JA, Lebrecht D, Messer A, Wolfgang WJ (2008). Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington’s disease. FASEB J. 22: 2003–2011.
[11] Abigail Snyder-Keller, Julie A. McLear, Tyisha Hathorn, and Anne Messer. (2010). Early or Late-Stage Anti-N-Terminal Huntingtin Intrabody Gene Therapy Reduces Pathological Features in B6.HDR6/1 Mice. Journal of Neuropathology & Experimental Neurology, 69 (10): 1078–1085.
[12] Butler DC, Messer A. (2011). Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments. PLoS One. 6(12):e29199. doi: 10.1371/journal.pone.0029199. Epub 2011 Dec 22.PMID: 2221621
[13] Gilon et al. (2000). Degradation signals recognized by the Ubc6p-Ubc7p Ubiquitin-conjugating enzyme pair. Molecular and Cellular Biology. 20 (19), 7214-7219.
[14] Bence, N. F., Sampat, R. M., and Kopito, R. R. (2001). Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 292, 1552–1555.
[15] Stefanovic-Barrett, S., Dickson, A. S., Burr, S. P., Williamson, J. C., Lobb, I. T., van den Boomen, D. J., et al. (2018). MARCH6 and TRC8 facilitate the quality control of cytosolic and tail-anchored proteins. EMBO Rep. 19, e45603.
[16] Daniela Gödderz 1, Ekaterine Schäfer, R Palanimurugan, R Jürgen Dohmen. (2011). The N-terminal unstructured domain of yeast ODC functions as a transplantable and replaceable ubiquitin-independent degron. J Mol Biol. Apr 1; 407(3): 354- 67.
[17] Schipper-Krom, S., Juenemann, K., & Reits, E. A. J. (2012). The Ubiquitin-Proteasome System in Huntington’s Disease: Are Proteasomes Impaired, Initiators of Disease, or Coming to the Rescue? Biochemistry research international, 2012, 837015.
[18] Krobitsch S, Lindquist S. (2000). Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc Natl Acad Sci Feb 15; 97(4): 1589-94.
[19] Wierson et al. (2020). Efficient targeted integration directed by short homology in zebrafish and mammalian cells. eLife 2020;9:e53968. DOI: https://doi.org/10.7554/eLife.53968
[20] Wang WW, Cao R, Rao ZR, Chen LW. Differential expression of NMDA and AMPA receptor subunits in DARPP- 32-containing neurons of the cerebral cortex, hippocampus and neostriatum of rats. Brain Res. 2004b; 998:174–183.
[21] Dabrowska et al., (2020). Generation of New Isogenic Models of Huntington ‘s Disease Using CRISPR-Cas9 Technology. Int. J. Mol. Sci. 2020, 21, 1854; doi:10.3390/ ijms21051854.
[22] Morozova, K.; Suldina, L.A.; Malankhanova, T.B.; Grigor’Eva, E.V.; Zakian, S.M.; Kiseleva, E.; Malakhova, A.A. Introducing an expanded CAG tract into the huntingtin gene causes a wide spectrum of ultrastructural defects in cultured human cells. PLoS ONE. 2018, 13, e0204735.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
